Targeting the Mitotic Kinesin KIF18A in Chromosomally Unstable Cancers: Hit Optimization Toward an In Vivo Chemical Probe

被引:17
|
作者
Tamayo, Nuria A. [1 ]
Bourbeau, Matthew P. [1 ]
Allen, Jennifer R. [1 ]
Ashton, Kate S. [1 ]
Chen, Jian Jeffrey [1 ]
Kaller, Matthew R. [1 ]
Nguyen, Thomas T. [1 ]
Nishimura, Nobuko [1 ]
Pettus, Liping H. [1 ]
Walton, Mary [1 ]
Belmontes, Brian [2 ]
Moriguchi, Jodi [2 ]
Chen, Kui [3 ]
McCarter, John D. [3 ]
Hanestad, Kelly [2 ]
Chung, Grace [2 ]
Ninniri, Maria Stefania S. [2 ]
Sun, Jan [2 ]
Poppe, Leszek [4 ]
Spahr, Chris [4 ]
Hui, John [4 ]
Jia, Lei [5 ]
Wu, Tian [6 ]
Dahal, Upendra P. [7 ]
Edson, Katheryne Z. [8 ]
Payton, Marc [2 ]
机构
[1] Amgen Res, Med Chem, Thousand Oaks, CA 91320 USA
[2] Amgen Res, Oncol Res, Thousand Oaks, CA 91320 USA
[3] Amgen Res, Discovery Technol, Thousand Oaks, CA 91320 USA
[4] Amgen Res, Discovery Attribute Sci, Thousand Oaks, CA 91320 USA
[5] Amgen Res, Computat & Data Sci, Thousand Oaks, CA 91320 USA
[6] Amgen Res, Prepivotal Drug Prod, Thousand Oaks, CA 91320 USA
[7] Amgen Res, Pharmacokinet & Drug Metab, San Francisco, CA 94080 USA
[8] Amgen Res, Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
关键词
STRUCTURAL BASIS; INHIBITOR; MITOSIS;
D O I
10.1021/acs.jmedchem.1c02030
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Chromosomal instability (CIN) is a hallmark of cancer that results from errors in chromosome segregation during mitosis. Targeting of CIN-associated vulnerabilities is an emerging therapeutic strategy in drug development. KIF18A, a mitotic kinesin, has been shown to play a role in maintaining bipolar spindle integrity and promotes viability of CIN cancer cells. To explore the potential of KIF18A, a series of inhibitors was identified. Optimization of aninitial hit led to the discovery of analogues that could be used as chemical probes to interrogate the role of KIF18A inhibition.Compounds23and24caused significant mitotic arrest in vivo, which was sustained for 24 h. This would be followed by cell death either in mitosis or in the subsequent interphase. Furthermore, photoaffinity labeling experiments reveal that this series of inhibitors binds at the interface of KIF18A and tubulin. This study represents the first disclosure of KIF18A inhibitors with in vivo activity
引用
收藏
页码:4972 / 4990
页数:19
相关论文
共 8 条
  • [1] Targeting the mitotic kinesin, KIF18A, in chromosomally unstable cancers
    Joseph, James D.
    Schutt, Katherine
    Fisher, Kira
    Queen, Katelyn
    Budington, Olivia
    Mao, Weifeng
    Liu, Wei
    Zhu, Zhengqing
    Zhang, Xiangping
    Xiao, Yisong
    Lai, Kunmin
    Gu, Xiaohui
    Stumpff, Jason
    Aswad, Fred
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers
    Marc Payton
    Brian Belmontes
    Kelly Hanestad
    Jodi Moriguchi
    Kui Chen
    John D. McCarter
    Grace Chung
    Maria Stefania Ninniri
    Jan Sun
    Raffi Manoukian
    Stuart Chambers
    Seok-Man Ho
    Robert J. M. Kurzeja
    Katheryne Z. Edson
    Upendra P. Dahal
    Tian Wu
    Sharon Wannberg
    Pedro J. Beltran
    Jude Canon
    Andrew S. Boghossian
    Matthew G. Rees
    Melissa M. Ronan
    Jennifer A. Roth
    Sheroy Minocherhomji
    Matthew P. Bourbeau
    Jennifer R. Allen
    Angela Coxon
    Nuria A. Tamayo
    Paul E. Hughes
    Nature Cancer, 2024, 5 : 66 - 84
  • [3] Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers
    Payton, Marc
    Belmontes, Brian
    Hanestad, Kelly
    Moriguchi, Jodi
    Chen, Kui
    Mccarter, John D.
    Chung, Grace
    Ninniri, Maria Stefania
    Sun, Jan
    Manoukian, Raffi
    Chambers, Stuart
    Ho, Seok-Man
    Kurzeja, Robert J. M.
    Edson, Katheryne Z.
    Dahal, Upendra P.
    Wu, Tian
    Wannberg, Sharon
    Beltran, Pedro J.
    Canon, Jude
    Boghossian, Andrew S.
    Rees, Matthew G.
    Ronan, Melissa M.
    Roth, Jennifer A.
    Minocherhomji, Sheroy
    Bourbeau, Matthew P.
    Allen, Jennifer R.
    Coxon, Angela
    Tamayo, Nuria A.
    Hughes, Paul E.
    NATURE CANCER, 2024, 5 (01) : 66 - 84
  • [4] Targeting chromosomally unstable tumors with a selective KIF18A inhibitor
    Phillips, Aaron F.
    Zhang, Rumin
    Jaffe, Mia
    Schulz, Ryan
    Carty, Marysol Chu
    Verma, Akanksha
    Feinberg, Tamar Y.
    Arensman, Michael D.
    Chiu, Alan
    Letso, Reka
    Bosco, Nazario
    Queen, Katelyn A.
    Racela, Allison R.
    Stumpff, Jason
    Andreu-Agullo, Celia
    Bettigole, Sarah E.
    Depetris, Rafael S.
    Drutman, Scott
    Su, Shinsan M.
    Cogan, Derek A.
    Eng, Christina H.
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [5] Targeting chromosomally unstable tumors with a selective KIF18A inhibitor
    Phillips, Aaron F.
    Zhang, Rumin
    Verma, Akanksha
    Feinberg, Tamar
    Jaffe, Mia
    Carty, Marysol Chu
    Schulz, Ryan
    Bettigole, Sarah
    Andreu, Celia
    Drutman, Scott
    Su, Michael
    Cogan, Derek
    Eng, Christina H.
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Discovery and preclinical characterization of novel small molecule inhibitors of kinesin KIF18A motor protein with potent activity against chromosomally unstable cancers.
    Sun, Jan
    Belmontes, Brain
    Moriguchi, Jodi
    Chung, Grace
    Chen, Kui
    McCarter, John D.
    Dahal, Upendra P.
    Boghossian, Andrew S.
    Rees, Matthew G.
    Ronan, Melissa M.
    Roth, Jennifer A.
    Minocherhomji, Sheroy
    Bourbeau, Matthew P.
    Allen, Jennifer R.
    Coxon, Angela
    Hughes, Paul E.
    Tamayo, Nuria
    Payton, Marc N.
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Discovery and preclinical characterization of AMG 650, a first-in-class inhibitor of kinesin KIF18A motor protein with potent activity against chromosomally unstable cancers
    Belmontes, Brian
    Moriguchi, Jodi
    Chung, Grace
    Sun, Jan
    Ninniri, Maria Stefania S.
    Hanestad, Kelly
    Chen, Kui
    McCarter, John D.
    Dahal, Upendra P.
    Ghimire-Rijal, Sudipa
    Hao, Yue
    Mohr, Christopher P.
    Yu, Xinchao
    Rees, Matthew G.
    Ronan, Melissa
    Roth, Jennifer
    Minocherhomji, Sheroy
    Allen, Jennifer R.
    Bourbeau, Matthew P.
    Hughes, Paul E.
    Tamayo, Nuria A.
    Payton, Marc N.
    CANCER RESEARCH, 2023, 83 (07)
  • [8] ISM9682A, a novel and potent KIF18A inhibitor, shows robust antitumor effects against chromosomally unstable cancers
    Zhang, Jie
    Gao, Feng
    Zhu, Wei
    Xu, Chenxi
    Ding, Xiaoyu
    Shang, Jing
    Qiao, Junwen
    Chen, Shan
    Cai, Xin
    Ding, Xiao
    Bavadekar, Supriya
    Rao, Sujata
    Zhang, Man
    Ren, Feng
    Zhavoronkov, Alex
    CANCER RESEARCH, 2024, 84 (06)